Fezagepras (Standard)

Fezagepras (Standard) is the analytical standard of Fezagepras. This product is intended for research and analytical applications. Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].

Product Specifications

CAS Number

[1002101-19-0]

Product Name Alternative

Setogepram (Standard) ; PBI-4050 (Standard)

UNSPSC

12352005

Target

Free Fatty Acid Receptor; GPR84; Reference Standards

Related Pathways

GPCR/G Protein; Others

Field of Research

Metabolic Disease; Inflammation/Immunology

Smiles

O=C(CC1=CC=CC(CCCCC)=C1)O

Molecular Formula

C13H18O2

Molecular Weight

206.28

References & Citations

[1]Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3 (10) . pii: 120365.|[2]Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367 (1) :71-81.